CIBC Asset Management Inc Buys 87 Shares of Masimo Co. (NASDAQ:MASI)

CIBC Asset Management Inc lifted its stake in shares of Masimo Co. (NASDAQ:MASI) by 5.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,631 shares of the medical equipment provider’s stock after acquiring an additional 87 shares during the quarter. CIBC Asset Management Inc’s holdings in Masimo were worth $270,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. FMR LLC lifted its holdings in Masimo by 41.2% in the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock worth $900,860,000 after purchasing an additional 1,970,883 shares during the last quarter. Westfield Capital Management Co. LP raised its position in shares of Masimo by 23.2% in the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after purchasing an additional 262,370 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Masimo by 916.1% in the fourth quarter. Assenagon Asset Management S.A. now owns 216,051 shares of the medical equipment provider’s stock worth $35,713,000 after buying an additional 194,788 shares during the last quarter. Clearline Capital LP bought a new stake in shares of Masimo during the 3rd quarter worth $21,337,000. Finally, ING Groep NV grew its stake in Masimo by 143.3% in the 3rd quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider’s stock valued at $32,119,000 after buying an additional 141,900 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on MASI. Raymond James boosted their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, January 22nd. Piper Sandler upped their price target on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Finally, Wells Fargo & Company raised their price objective on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Masimo presently has a consensus rating of “Moderate Buy” and an average price target of $191.40.

Masimo Price Performance

Shares of NASDAQ:MASI opened at $170.72 on Tuesday. The firm has a market capitalization of $9.14 billion, a PE ratio of 117.74 and a beta of 1.02. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $184.51. The business’s 50 day moving average is $172.65 and its 200-day moving average is $152.54.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.